GAPDH overexpression is also associated with reduced patient survival (Guo et al, 2013), and therapeutic targeting of GAPDH has been demonstrated to have clinical application in both hepatocellular and colorectal cancers (Ganapathy‐Kanniappan et al, 2012; Yun et al, 2015). The gene discussed is GAPDH; the disease is colorectal cancer.